Purpose. The mechanism by which laser trabeculoplasty reduces elevated
intraocular pressure in primary open-angle glaucoma has not been esta
blished. To test the hypothesis that trabecular extracellular matrix t
urnover is involved, stromelysin expression after laser treatment of a
nterior segment organ cultures was evaluated. Methods. Argon laser tra
beculoplasty, using typical clinical treatment parameters, was applied
to anterior segment organ cultures. Stromelysin levels and activity w
ere then evaluated at various times by immunoblots of Western transfer
s and by zymography. Stromelysin mRNA levels were evaluated by dot blo
t and by reverse transcription, followed by polymerase chain reaction
amplification. Stromelysin protein was localized by immunohistochemist
ry, and image analysis was used for quantitation. Stromelysin mRNA was
localized by in situ hybridization. Results, Trabecular stromelysin p
rotein, activity, and mRNA levels were detectably elevated by 8 hours
and were several-fold higher by 24 hours after treatment. Stromelysin
immunostaining was elevated dramatically in the juxtacanalicular and i
nsert regions of the meshwork, but only modestly in other regions. Str
omelysin mRNA increases also were localized primarily to these regions
. The juxtacanalicular stromelysin immunostaining increase was sustain
ed for at least 1 week, whereas the insert levels declined somewhat af
ter day 2. Conclusions. A stromelysin increase, localized primarily to
the juxtacanalicular region of the meshwork, the putative site of the
aqueous humor outflow resistance, should degrade trabecular proteogly
cans, the putative outflow resistance source, and allow their uptake a
nd further degradation by the juxtacanalicular cells. If diminished ju
xtacanalicular extracellular matrix turnover is responsible for the gl
aucomatous reduction in aqueous humor outflow, an increase in stromely
sin in this specific area of the meshwork should ameliorate the proble
m. Thus, the observations support the working hypothesis and may expla
in the efficacy of this treatment for glaucoma.